Burns - Pipeline Review, H2 2017

Date: August 16, 2017
Pages: 94
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BE99E0EA53AEN
Leaflet:

Download PDF Leaflet

Burns - Pipeline Review, H2 2017
Burns - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burns - Pipeline Review, H2 2017, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burns - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 4, 1, 14, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Burns - Overview
Burns - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Burns - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Burns - Companies Involved in Therapeutics Development
AlgiPharma AS
Alliance Pharma Plc
Amarantus Bioscience Holdings Inc
American Gene Technologies International Inc
Anterogen Co Ltd
CytoTools AG
Destiny Pharma Ltd
Lakewood-Amedex Inc
Madam Therapeutics BV
MediWound Ltd
Phagelux Inc
Phosphagenics Ltd
Se-cure Pharmaceuticals Ltd
Stratatech Corp
USV Pvt Ltd
Burns - Drug Profiles
(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile
A-3APO - Drug Profile
AG-110 - Drug Profile
albumin (recombinant) - Drug Profile
AyuV-25 - Drug Profile
Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis - Drug Profile
bromelains - Drug Profile
Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile
Cell Therapy for Dermatology and Immunology - Drug Profile
ENERGIF-711 - Drug Profile
epidermal growth factor biosimilar - Drug Profile
Gene Therapy for Burns - Drug Profile
IMSP-001 - Drug Profile
ISN-001 - Drug Profile
lidocaine hydrochloride - Drug Profile
Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile
Neu-2000 - Drug Profile
NJ-01SS - Drug Profile
Nu-2 - Drug Profile
Oligomer G for Burn Wounds - Drug Profile
P-12 - Drug Profile
P-148 - Drug Profile
PEP-04 - Drug Profile
Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile
Recombinant Protein to Agonize EPCR for Wounds and Burns - Drug Profile
SC-106 - Drug Profile
SFR-9X0125 - Drug Profile
silver sulfadiazine - Drug Profile
Small Molecules for Burns - Drug Profile
sodium hypochlorite - Drug Profile
SST-024 - Drug Profile
Vanadis-02 - Drug Profile
XF-70 - Drug Profile
Burns - Dormant Projects
Burns - Discontinued Products
Burns - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Burns, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Burns - Pipeline by AlgiPharma AS, H2 2017
Burns - Pipeline by Alliance Pharma Plc, H2 2017
Burns - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
Burns - Pipeline by American Gene Technologies International Inc, H2 2017
Burns - Pipeline by Anterogen Co Ltd, H2 2017
Burns - Pipeline by CytoTools AG, H2 2017
Burns - Pipeline by Destiny Pharma Ltd, H2 2017
Burns - Pipeline by Lakewood-Amedex Inc, H2 2017
Burns - Pipeline by Madam Therapeutics BV, H2 2017
Burns - Pipeline by MediWound Ltd, H2 2017
Burns - Pipeline by Phagelux Inc, H2 2017
Burns - Pipeline by Phosphagenics Ltd, H2 2017
Burns - Pipeline by Se-cure Pharmaceuticals Ltd, H2 2017
Burns - Pipeline by Stratatech Corp, H2 2017
Burns - Pipeline by USV Pvt Ltd, H2 2017
Burns - Dormant Projects, H2 2017
Burns - Dormant Projects, H2 2017 (Contd.1), H2 2017
Burns - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Burns, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

AlgiPharma AS
Alliance Pharma Plc
Amarantus Bioscience Holdings Inc
American Gene Technologies International Inc
Anterogen Co Ltd
CytoTools AG
Destiny Pharma Ltd
Lakewood-Amedex Inc
Madam Therapeutics BV
MediWound Ltd
Phagelux Inc
Phosphagenics Ltd
Se-cure Pharmaceuticals Ltd
Stratatech Corp
USV Pvt Ltd
Skip to top


NeurAxon, Inc. - Product Pipeline Review - 2014 US$ 1,500.00 Sep, 2014 · 23 pages

Ask Your Question

Burns - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: